...
search icon
stro-img

Sutro Biopharma Share Price

STRO
NMQ
$18.834
-$0.73
(-3.73%)
1D
Industry: Biotechnology Sector: Health Care

Sutro Biopharma Analyst Forecast

Sutro Biopharma Share Price Chart

Sutro Biopharma Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$320.54M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
96.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.61
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.23 L
$19.9 H
$18.834

About Sutro Biopharma, Common Stock

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Sutro Biopharma Stock Returns

Time FrameSTROSectorS&P500
1-Week Return25.22%0.81%0.49%
1-Month Return31.1%1.2%1.02%
3-Month Return114.95%3.24%3.34%
6-Month Return126.97%14.99%7.04%
1-Year Return4.6%7.42%11.68%
3-Year Return-67.88%20.71%71.63%
5-Year Return-92%37.45%75.56%
10-Year Return-87.13%138.53%257.55%

Sutro Biopharma Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue42.72M61.88M67.77M153.73M62.04M[{"date":"2020-12-31","value":27.79,"profit":true},{"date":"2021-12-31","value":40.25,"profit":true},{"date":"2022-12-31","value":44.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":40.36,"profit":true}]
Cost of Revenue76.96M9.77M8.29M6.82M7.22M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":12.7,"profit":true},{"date":"2022-12-31","value":10.77,"profit":true},{"date":"2023-12-31","value":8.86,"profit":true},{"date":"2024-12-31","value":9.38,"profit":true}]
Gross Profit(34.24M)52.11M59.48M146.91M54.83M[{"date":"2020-12-31","value":-23.31,"profit":false},{"date":"2021-12-31","value":35.47,"profit":true},{"date":"2022-12-31","value":40.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":37.32,"profit":true}]
Gross Margin(80.14%)84.21%87.77%95.57%88.37%[{"date":"2020-12-31","value":-83.86,"profit":false},{"date":"2021-12-31","value":88.11,"profit":true},{"date":"2022-12-31","value":91.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":92.47,"profit":true}]
Operating Expenses36.82M150.63M188.43M236.19M293.28M[{"date":"2020-12-31","value":12.55,"profit":true},{"date":"2021-12-31","value":51.36,"profit":true},{"date":"2022-12-31","value":64.25,"profit":true},{"date":"2023-12-31","value":80.54,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(71.06M)(98.52M)(128.94M)(89.28M)(238.45M)[{"date":"2020-12-31","value":-7105700000,"profit":false},{"date":"2021-12-31","value":-9852400000,"profit":false},{"date":"2022-12-31","value":-12894300000,"profit":false},{"date":"2023-12-31","value":-8927800000,"profit":false},{"date":"2024-12-31","value":-23845300000,"profit":false}]
Total Non-Operating Income/Expense36.36M(9.57M)12.35M(1.57M)26.71M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-26.33,"profit":false},{"date":"2022-12-31","value":33.96,"profit":true},{"date":"2023-12-31","value":-4.31,"profit":false},{"date":"2024-12-31","value":73.46,"profit":true}]
Pre-Tax Income(32.13M)(105.54M)(116.70M)(88.60M)(225.10M)[{"date":"2020-12-31","value":-3212800000,"profit":false},{"date":"2021-12-31","value":-10553800000,"profit":false},{"date":"2022-12-31","value":-11670400000,"profit":false},{"date":"2023-12-31","value":-8860100000,"profit":false},{"date":"2024-12-31","value":-22509800000,"profit":false}]
Income Taxes4.08M3.14M2.50M18.19M2.36M[{"date":"2020-12-31","value":22.41,"profit":true},{"date":"2021-12-31","value":17.24,"profit":true},{"date":"2022-12-31","value":13.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":12.99,"profit":true}]
Income After Taxes(36.20M)(108.67M)(119.20M)(106.79M)(227.46M)[{"date":"2020-12-31","value":-3620500000,"profit":false},{"date":"2021-12-31","value":-10867500000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-10679300000,"profit":false},{"date":"2024-12-31","value":-22746100000,"profit":false}]
Income From Continuous Operations(32.13M)(105.54M)(119.20M)(172.45M)(227.46M)[{"date":"2020-12-31","value":-3212800000,"profit":false},{"date":"2021-12-31","value":-10553800000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-17245200000,"profit":false},{"date":"2024-12-31","value":-22746100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(32.13M)(105.54M)(119.20M)(106.79M)(227.46M)[{"date":"2020-12-31","value":-3212800000,"profit":false},{"date":"2021-12-31","value":-10553800000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-10679300000,"profit":false},{"date":"2024-12-31","value":-22746100000,"profit":false}]
EPS (Diluted)(2.46)(2.29)(2.44)(1.78)(2.67)[{"date":"2020-12-31","value":-246,"profit":false},{"date":"2021-12-31","value":-229,"profit":false},{"date":"2022-12-31","value":-244,"profit":false},{"date":"2023-12-31","value":-178,"profit":false},{"date":"2024-12-31","value":-267.14,"profit":false}]

Sutro Biopharma Ratios

Sutro Biopharma Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

STRO
Cash Ratio 2.33
Current Ratio 2.53

Sutro Biopharma Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

STRO
ROA (LTM) -25.80%
ROE (LTM) -1810.01%

Sutro Biopharma Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

STRO
Debt Ratio Lower is generally better. Negative is bad. 1.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.42

Sutro Biopharma Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

STRO
Trailing PE NM
Forward PE 10.03
P/S (TTM) 2.70
P/B 2.11
Price/FCF NM
EV/R 1.06
EV/Ebitda 0.41

FAQs

What is Sutro Biopharma share price today?

Sutro Biopharma (STRO) share price today is $18.834

Can Indians buy Sutro Biopharma shares?

Yes, Indians can buy shares of Sutro Biopharma (STRO) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in STRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sutro Biopharma be purchased?

Yes, you can purchase fractional shares of Sutro Biopharma (STRO) via the Vested app. You can start investing in Sutro Biopharma (STRO) with a minimum investment of $1.

How to invest in Sutro Biopharma shares from India?

You can invest in shares of Sutro Biopharma (STRO) via Vested in three simple steps:

  • Click on Sign Up or Invest in STRO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sutro Biopharma shares
What is Sutro Biopharma 52-week high and low stock price?

The 52-week high price of Sutro Biopharma (STRO) is $19.9. The 52-week low price of Sutro Biopharma (STRO) is $5.23.

What is Sutro Biopharma price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sutro Biopharma (STRO) is

What is Sutro Biopharma price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sutro Biopharma (STRO) is 2.11

What is Sutro Biopharma dividend yield?

The dividend yield of Sutro Biopharma (STRO) is 0.00%

What is the Market Cap of Sutro Biopharma?

The market capitalization of Sutro Biopharma (STRO) is $320.54M

What is Sutro Biopharma's stock symbol?

The stock symbol (or ticker) of Sutro Biopharma is STRO

How Can Investors Use Sutro Biopharma Share Price Data for Long-Term Investment Decisions?

Consider the share price of Sutro Biopharma as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Sutro Biopharma has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Sutro Biopharma shares for Indian investors?

When investing in Sutro Biopharma shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Sutro Biopharma stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Sutro Biopharma share price with other stocks in the same sector?

Rather than merely checking the share price of Sutro Biopharma and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Sutro Biopharma stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top